

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Antonio Marchetti et al.**Application No.:** To be assigned**Filed:** Herewith**Confirmation No.:** To be assigned**For:** NUCLEOTIDE AND DEDUCED AMINO  
ACID SEQUENCES OF TUMOR GENE  
INT6**Examiner:** To be assigned**Art Unit:** To be assigned**Attorney Reference No.:** 4239-67782**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV331581431US in an envelope addressed to: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent  
for Applicant(s)Date Mailed February 19, 2004

MAIL STOP PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
FOR CONTINUING APPLICATIONS**

Listed on the accompanying form PTO-1449 are several English-language documents. Applicants respectfully request that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/858,152, which was filed May 14, 2001, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicants in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicants will furnish the Patent Office with such copies upon request.


Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

  
\_\_\_\_\_  
Susan Alpert Siegel, Ph.D.  
Registration No. 43,121

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Attorney Docket Number</b>	4239-67782
				<b>Application Number</b>	To be assigned
				<b>Filing Date</b>	Herewith
				<b>First Named Inventor</b>	Antonio Marchetti
				<b>Art Unit</b>	To be assigned
				<b>Examiner Name</b>	To be assigned
<b>U.S. PATENT DOCUMENTS</b>					
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>Number</b>	<b>Date</b>	<b>Name</b>	
<b>FOREIGN PATENT DOCUMENTS</b>					
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>Number</b>	<b>Date</b>	<b>Country</b>	
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>			
		Dickson et al., <i>Cell</i> 37:529-536, 1984			
		Diella et al., <u>10<sup>th</sup> Annual Meeting on Oncogenes</u> , Frederick, MD, 1994			
		Diella et al., <i>DNA and Cell Bio.</i> 16:839-847, 1997			
		Gallahan et al., <i>J. Virol.</i> 61(1):66-74, 1987			
		Jhappen et al., <i>Genes &amp; Develop.</i> , 6:345-355, 1992			
		Marchetti et al., <u>7<sup>th</sup> Annual Meeting on Oncogenes</u> , Frederick, MD, 1991			
		Marchetti et al., <i>J. Virol.</i> 69(3):1932-1938, 1995			
		Miyazaki et al., <u>9<sup>th</sup> Annual Meeting on Oncogenes</u> , Frederick, MD, 1993			
		Miyazaki et al., <i>Genomics</i> 27:420-424, 1995			
		Muller et al., <i>Embo. J.</i> 9:907-913, 1990			
		Nucleic Acid Sequence having GenBank Accession No. D11956			
		Nucleic Acid Sequence having GenBank Accession No. Z25267			
<b>EXAMINER SIGNATURE:</b>			<b>DATE CONSIDERED:</b>		
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.					

[illegible]

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	